AMGEN CEO: WILL BIOTECHNOLOGY SURVIVE THE CLINTON HEALTH CARE REFORMS?
WASHINGTON, Oct. 15 /PRNewswire/ -- Speaking before a National Press Club-sponsored luncheon, Gordon Binder, chairman and CEO of Amgen Inc. (NASDAQ-NMS: AMGN), said the future of the biotechnology industry "depends on what kind of reforms evolve out of the tortuous and tumultuous year-long legislative and political process that has only just begun." Binder added, "But, as this debate commences, it is crucial that in the process of reforming one-seventh of the nation's economy, we do not allow the weakening or destruction of an industry whose products hold the promise of improved lives and reduced costs to the overall health care system." Binder said he is "optimistic that the end result of this process will preserve that promise ... because biotechnology's future is simply too important and too full of potential to be sidetracked by the only policy that would deal it a fatal blow -- price controls on breakthrough drugs." Amgen Inc., headquartered in Thousand Oaks, Calif., is the world's leading manufacturer of biologically derived human therapeutics. -0- 10/15/93 /NOTE TO EDITORS: Copies of Binder's remarks are available by calling the contact below./ /CONTACT: Peter Teeley of Amgen, 202-452-7074, or Bob Neuman, 202-628-2075, for Amgen/ (AMGN)
CO: Amgen Inc. ST: District of Columbia IN: MTC HEA SU:
DC-DT -- DC021 -- 2879 10/15/93 15:49 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 15, 1993|
|Previous Article:||WCI STEEL, INC. TO INCREASE FLAT ROLLED BASE PRICES|
|Next Article:||BIEBER, MARSHALL ANNOUNCE RATIFICATION OF NEW UAW-CHRYSLER AGREEMENTS|